Amlodipine

From Self-sufficiency
Revision as of 22:08, 23 June 2010 by SieBot (Talk) (robot Adding: uk:Амлодипін)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Amlodipine
260px
260px
Systematic (IUPAC) name
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
Clinical data
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration
Oral (tablets)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 64 to 90%
Metabolism HepaticNikhil and Nilesh filed a patent on amlodipine
Biological half-life 30 to 50 hours
Excretion Renal
Identifiers
CAS Number 88150-42-9
ATC code C08CA01 (WHO)
PubChem CID 2162
DrugBank APRD00520
ChemSpider 2077
Chemical data
Formula C20H25ClN2O5
Molar mass 408.879 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Amlodipine (as besylate, mesylate or maleate) is a long-acting calcium channel blocker (dihydropyridine class) used as an anti-hypertensive and in the treatment of angina. Like other calcium channel blockers, amlodipine acts by relaxing the smooth muscle in the arterial wall, decreasing total peripheral resistance and hence reducing blood pressure; in angina it increases blood flow to the heart muscle.

Indications

Cautions

Contraindications

Amlodipine causes vasodilatation, which in patients with severe aortic stenosis, can result in reduced cardiac output.

There is not absolute consensus about the contraindication, because if the patient has hypertension, his stenosis cannot be very severe, otherwise he would not have sufficient output to allow hypertension.[1]

Side effects

Some side effects of the use of amlodipine may be:[2]

Dose

  • Hypertension or angina: 2.5 to 10 mg once daily (initial treatment can start as low as 2.5 mg per day, titrate up to 10 mg/day as necessary).

Salts

In the United Kingdom tablets of amlodipine from different suppliers may contain different salts. The strength of the tablets is expressed in terms of amlodipine base, i.e., without the salt. Tablets containing different salts are therefore considered interchangeable.

The efficacy and tolerability of a fixed-dose combination of amlodipine 5 mg and perindopril 4 mg, an angiotensin converting enzyme (ACE) inhibitor, have recently been confirmed in a prospective, observational multicentre trial of 1250 hypertensive patients.[3]

Drug metabolism and excretion

Amlodipine is almost entirely metabolised to inactive metabolites. 10% of the parent substance and 60% of the metabolites are excreted in urine.

Stereoisomerism

Amlodipine is a chiral calcium antagonist, currently on the market and in therapeutic use as a racemate [1:1 mixture of (R)-(+)- and (S)-(–)-amlodipine][4]. A method for the semi-preparative chromatographic purification of the enantiomers (S)-(–)-amlodipine and (R)-(+)-amlodipine has been reported.[5]

Patent loss

Pfizer patent protection on Norvasc lasted until 2007. Total patent expiration occurred later in 2007.[6] A number of generic versions are available.

Brand names

Amlodipine is marketed as:

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

ar:أملوديبين

bg:Амлодипин de:Amlodipin es:Amlodipina fa:آملودیپین fr:Amlodipine it:Amlodipina hu:Amlodipin nl:Amlodipine ja:アムロジピン pl:Amlodypina pt:Anlodipino ru:Амлодипин

uk:Амлодипін
  1. Does it matter how severe is the stenosis? NHS July 19, 2006
  2. Source: Sandoz product information sheet
  3. Bahl VK, Jadhav UM, Thacker HP (2009). "Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study". Am J Cardiovasc Drugs. 9 (3): 135–42. doi:10.2165/00129784-200909030-00001. PMID 19463019. 
  4. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  6. Kennedy, Val Brickates (2007-03-22). "Pfizer loses court ruling on Norvasc patent". MarketWatch.